Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Myriad Genetics (MYGN) over the last 12 years, with Q3 2025 value amounting to $4.8 million.

  • Myriad Genetics' Depreciation and Depletion changed 0.0% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 645.16%. This contributed to the annual value of $19.5 million for FY2024, which is 209.42% up from last year.
  • Per Myriad Genetics' latest filing, its Depreciation and Depletion stood at $4.8 million for Q3 2025, which was down 0.0% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Depreciation and Depletion ranged from a high of $8.7 million in Q1 2023 and a low of $2.6 million during Q3 2021
  • For the 5-year period, Myriad Genetics' Depreciation and Depletion averaged around $4.0 million, with its median value being $3.4 million (2021).
  • In the last 5 years, Myriad Genetics' Depreciation and Depletion surged by 21071.43% in 2023 and then tumbled by 4367.82% in 2024.
  • Myriad Genetics' Depreciation and Depletion (Quarter) stood at $3.2 million in 2021, then decreased by 3.12% to $3.1 million in 2022, then surged by 38.71% to $4.3 million in 2023, then grew by 16.28% to $5.0 million in 2024, then dropped by 4.0% to $4.8 million in 2025.
  • Its Depreciation and Depletion stands at $4.8 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.1 million for Q1 2025.